42753-71-9

Basic information

• Product Name: 2-Amino-5-bromo-6-methylpyridine
• Synonyms: 6-Amino-3-bromo-2-methylpyridine ,98%;2-Methyl-3-bromo-6-aminopyridine;5-Bromo-6-methyl-2-pyridinamine;5-Bromo-6-methylpyridine-2-amine;6-Amino-3-bromo-2-picoline,98%;2-amine-5-bromo-6-methylpyridine;2 - aMino - 5 - broMine - 6 - Methyl pyridine;6-Amino-3-bromo-2-methylpyridine,97%
• CAS NO: 42753-71-9
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• EINECS: 255-927-5
• Product Categories: Halopyridines;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Amino-pyridine series;Heterocycle-Pyridine series;compounds of pyridine;blocks;Bromides;Pyridines;Pyridine;Amines and Anilines;Heterocycles;Pyridines, Pyrimidines, Purines and Pteredines;Amines;Bromopyridines
• Mol File: 42753-71-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 79-84 °C(lit.)
• Boiling Point: 234.3 °C at 760 mmHg
• Flash Point: 95.5 °C
• Appearance: White to off-white/Fluffy Powder
• Density: 1.5672 (rough estimate)
• Vapor Pressure: 0.0534mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 4.80±0.37(Predicted)
• Sensitive: Hygroscopic
• BRN: 114140
• CAS DataBase Reference: 2-Amino-5-bromo-6-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-bromo-6-methylpyridine(42753-71-9)
• EPA Substance Registry System: 2-Amino-5-bromo-6-methylpyridine(42753-71-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-26/37/39
• WGK Germany: 3
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 42753-71-9(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow Cryst

InChI:InChI=1/C6H7BrN2/c1-4-5(7)2-3-6(8)9-4/h2-3H,1H3,(H2,8,9)/p+1

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 3430-17-9 2-bromo-3-picoline 

Downstream Products

• 116355-19-2 6-bromo-5-methylimidazo<1,2-a>pyridine 
• 375368-83-5 3-bromo-6-fluoro-2-methyl-pyridine 
• 910054-73-8 (5-bromo-6-methyl-pyridin-2-yl)-dimethyl-amine 
• 59352-90-8 2,3-diamino-5-bromo-6-methylpyridine 
• 28279-41-6 6-bromo-5-methylimidazo[4,5-b]pyridine 
• 155790-09-3 N-2,6-dimethyl-2,3-pyridinediamine 
• 155789-83-6 2-amino-3,5-dimethylimidazo<4,5-b>pyridine 
• 183428-90-2 2-amino-5-cyano-6-methylpyridine 
• 1104066-46-7 3-(5-bromo-6-methylpyridin-2-yl)-2-(2,6-dibromophenyl)thiazolidin-4-one 
• 1029127-96-5 N-(5-bromo-6-methylpyridin-2-yl)-2,2-dimethylbutanamide 
• 1267854-50-1 5-bromo-6-methyl-N-tritylpyridin-2-amine 
• 1360551-80-9 2-[4-(3-{(R)-1-[4-(6-amino-2-methyl-pyridin-3-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 1374131-28-8 3-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}propanoic acid 
• 1374131-12-0 methyl 5-{3-[6-azetidin-1-yl-2-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)pyridin-3-yl]-4-methoxyphenyl}-2-furoate 

Relevant articles and documents

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

Synthesis method of nitrogen-containing deuterated methyl compound

The invention discloses a synthesis method of a nitrogen-containing deuterated methyl compound. The method comprises the following steps: 2-amino-6-methylpyridine used as an initial raw material reacts with an aprotic solution of N-bromosuccinimide, separation is performed to obtain a compound 1, the compound 1 is subjected to an iodination reaction, palladium catalysis, cyclization, hydroxyl trifluoromethanesulfonic acid anhydridization and a deuteration reaction, and then extraction, organic phase mixing, saturated salt water washing, drying, spin-drying, column separation and other post-treatments to obtain the final product. The raw material has a low cost and is easy to obtain, so compared with other synthesis routes, the synthesis method of the nitrogen-containing deuterated methyl compound has the advantages of obvious reduction of the cost, good separation effect, few impurities, suitableness for large-scale production, and increase of the demethylation synthesis yield; the deuterated product can be effectively obtained through method, the deuteration rate can reach 97%, the production temperature is not higher than 100 DEG C to easily achieve safe production, and the practical value is high.

multi-links class PI3K inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular of formula (I) shown in multi-links class of PI3K inhibitors, its stereoisomers or its pharmaceutically acceptable salt thereof, wherein the R 1, R 2, R 3, R 4 or R 5 as defined in the specification; the invention also relates to methods of preparing such compounds, pharmaceutical compositions of these compounds in the preparation and treatment and/or prevention of proliferative diseases of the use of the medicament. (by machine translation)

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Preparation method of 2-amino-5-methyl-6-bromopyridine

For overcoming defects in the prior art, the invention provides a preparation method of 2-amino-5-methyl-6-bromopyridine, which belongs to the technical field of synthesis of pharmaceutical intermediates. The method comprises the following steps: adding an organic solvent subjected to water removal into sodamide under the protection of nitrogen, then heating a solution, and after 2-bromo-3-methylpyridine is added, carrying out reflux reaction on the obtained mixture under the condition that the temperature is kept; and after the reaction is completed, cooling the solution, adding ice water, separating out an upper organic solvent, and sequentially carrying out concentration and crystallization on the organic solvent, so that a product is obtained. According to the invention, a product is directly obtained through one-step amination, therefore, the method is safe and simple in process, and suitable for industrial production.

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against mycobacterium tuberculosis

DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restrict their clinical value. We describe a novel class of N-linked aminopiperidinyl alkyl quinolones and naphthyridones that kills Mtb by inhibiting the DNA gyrase activity. The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as shown by their ability to inhibit the growth of fluoroquinolone-resistant Mtb. Biochemical studies demonstrated this class to exert its action via single-strand cleavage rather than double-strand cleavage, as seen with fluoroquinolones. The compounds are highly bactericidal against extracellular as well as intracellular Mtb. Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability. Compounds from this series are efficacious in various murine models of tuberculosis.

A mild method for the regioselective bromination of 2-aminopyridines

An efficient and regioselective bromination of 2-aminopyridines was developed. The environmental friendly bromination occurs under mild and clean conditions using readily available 1-butylpyridinium bromide as the bromine source and hydrogen peroxide as the green oxidant.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Improvement of the synthesis of 6-bromo-5-methylimidazo[4,5-b]pyridine, a stabilizer for color photography

Procedures were suggested for preparing 6-bromo-5-methylimidazo[4,5-b] pyridine, a stabilizer for TsMF-2 color photographic moment, a component of developing pastes of the photographic kit.

PYRIDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

Substituted pyridyl imidazole derivatives of formula (I) inhibit effectively the action of angiotensin II and have a superior anti-hypertensive activity. STR1